HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peter Langmann Selected Research

Antibodies

1/2021Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Peter Langmann Research Topics

Disease

1Ulcerative Colitis
01/2021
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2021
1Crohn Disease (Crohn's Disease)
01/2021
1Renal Cell Carcinoma (Grawitz Tumor)
07/2011
1Hepatocellular Carcinoma (Hepatoma)
07/2011
1Liver Diseases (Liver Disease)
05/2008
1Lipodystrophy
09/2005
1Paraplegia (Spastic Paraplegia)
09/2005
1Lipomatosis
09/2005
1Neurologic Manifestations (Neurological Manifestations)
09/2005
1HIV Infections (HIV Infection)
05/2004
1Encephalitis (Encephalitis, Rasmussen)
05/2004

Drug/Important Bio-Agent (IBA)

2Protease Inhibitors (Protease Inhibitor)IBA
09/2005 - 05/2004
1AntibodiesIBA
01/2021
1Infliximab (Remicade)FDA Link
01/2021
1Sorafenib (BAY 43-9006)FDA Link
07/2011
1N 30IBA
05/2008
1LopinavirFDA Link
05/2008
1SteroidsIBA
09/2005
1Adrenal Cortex Hormones (Corticosteroids)IBA
09/2005
1Pharmaceutical PreparationsIBA
05/2004
1Pyrimethamine (Daraprim)FDA Link
05/2004

Therapy/Procedure

4Therapeutics
01/2021 - 05/2004
1Laminectomy
09/2005
1Highly Active Antiretroviral Therapy (HAART)
05/2004